title: Patient, Caregiver, and Nurse Preferences for Treatments for Bone Metastases from Solid Tumors.
abstract: Bone-targeted agents (BTAs) used for the prevention of skeletal-related events (SREs) associated with metastatic bone disease possess different attributes that factor into treatment decisions.
  
  
  
  The aim of this study was to evaluate preferences of patients, caregivers, and nurses for features of BTAs used to prevent SREs in patients with a self-reported physician diagnosis of bone metastasis from solid tumors.
  
  
  
  Patients (n = 187), primary caregivers (n = 197), or nurses (n = 196) completed a web-enabled discrete-choice experiment (10-question survey) in which they chose between pairs of hypothetical profiles of BTAs. Each profile was defined by six key treatment attributes, including efficacy and safety (two each) and route/frequency of administration and cost (one each). The relative importance of treatment attributes and levels was estimated.
  
  
  
  The most important treatment attribute for patients and nurses was out-of-pocket cost, and for caregivers, treatment-related risk of renal impairment. Risk of renal impairment was the second most important attribute for patients and nurses, while time until first SRE was the third most important attribute for all respondents. For nurses, risk of osteonecrosis of the jaw was least important, and for patients and caregivers, mode of administration was least important.
  
  
  
  Respondents considered hypothetical medications; therefore, their decisions may not have the same consequences as actual decisions.
  
  
  
  The perspectives of patients, caregivers, and nurses are integral when making treatment decisions about BTAs to prevent SREs associated with solid tumors. Identifying the relative importance of attributes of BTAs will aid in the proper selection of therapy in this setting, which may improve patient outcomes.
authors.affiliation: Amgen Inc., One Amgen Center Drive, M/S 28-3-A, Thousand Oaks, CA, 91320, USA. yiq@amgen.com.
authors.forename: Yi
authors.initials: Y
authors.lastname: Qian
authors.affiliation: Amgen Inc., One Amgen Center Drive, M/S 28-3-A, Thousand Oaks, CA, 91320, USA.
authors.forename: Jorge
authors.initials: J
authors.lastname: Arellano
authors.affiliation: RTI Health Solutions, Research Triangle Park, NC, USA.
authors.forename: A Brett
authors.initials: AB
authors.lastname: Hauber
authors.affiliation: RTI Health Solutions, Research Triangle Park, NC, USA.|Bayer HealthCare Pharmaceuticals Inc., Whippany, NJ, USA.
authors.forename: Ateesha F
authors.initials: AF
authors.lastname: Mohamed
authors.affiliation: RTI Health Solutions, Research Triangle Park, NC, USA.
authors.forename: Juan Marcos
authors.initials: JM
authors.lastname: Gonzalez
authors.affiliation: Amgen (Europe) GmbH, Zug, Switzerland.
authors.forename: Guy
authors.initials: G
authors.lastname: Hechmati
authors.affiliation: Amgen (Europe) GmbH, Zug, Switzerland.
authors.forename: Francesca
authors.initials: F
authors.lastname: Gatta
authors.affiliation: Carolina Urologic Research Center, Myrtle Beach, SC, USA.
authors.forename: Stacey
authors.initials: S
authors.lastname: Harrelson
authors.affiliation: Pennsylvania State University Milton S. Hershey Medical Center, Hershey, PA, USA.
authors.forename: Cynthia
authors.initials: C
authors.lastname: Campbell-Baird
mesh_terms: D000328:Adult; D001291:Attitude of Health Personnel; D001859:Bone Neoplasms / Q000188:drug therapy* / Q000556:secondary*; D017028:Caregivers / Q000523:psychology*; D002755:Choice Behavior; D004333:Drug Administration Routes; D004334:Drug Administration Schedule; D064420:Drug-Related Side Effects and Adverse Reactions; D005260:Female; D005102:Health Expenditures; D006801:Humans; D008297:Male; D008875:Middle Aged; D009726:Nurses / Q000523:psychology*; D057240:Patient Preference; D018570:Risk Assessment; D011795:Surveys and Questionnaires; D013997:Time Factors
references.citation: Patient. 2010 Dec 1;3(4):249-56
references.pmid: 22273432
references.citation: Cancer. 1997 Oct 15;80(8 Suppl):1588-94
references.pmid: 9362426
references.citation: Psychooncology. 2013 Nov;22(11):2624-31
references.pmid: 23893390
references.citation: N Engl J Med. 2004 Oct 7;351(15):1502-12
references.pmid: 15470213
references.citation: Prostate. 2014 Nov;74(15):1488-97
references.pmid: 25132622
references.citation: Oncol Nurs Forum. 2012 Jan;39(1):E70-83
references.pmid: 22201670
references.citation: Lung Cancer. 2012 Jul;77(1):224-31
references.pmid: 22369719
references.citation: Support Care Cancer. 2014 Jun;22(6):1601-10
references.pmid: 24477326
references.citation: Oncology. 2004;67(5-6):390-6
references.pmid: 15713995
references.citation: Alzheimer Dis Assoc Disord. 2009 Jan-Mar;23(1):23-32
references.pmid: 18725862
references.citation: Oncol Nurs Forum. 2014 Jul 1;41(4):411-9
references.pmid: 24969250
references.citation: Eur J Cancer. 2012 Nov;48(16):3082-92
references.pmid: 22975218
references.citation: Support Care Cancer. 2014 Jan;22(1):103-13
references.pmid: 24000042
references.citation: Support Care Cancer. 2013 Jun;21(6):1785-91
references.pmid: 23519570
references.citation: Cancer. 2000 Jul 15;89(2):363-8
references.pmid: 10918167
references.citation: Value Health. 2011 Jun;14(4):403-13
references.pmid: 21669364
references.citation: Cancer. 2002 Apr 1;94(7):2076-80
references.pmid: 11932912
references.citation: Breast Cancer Res Treat. 2012 Oct;135(3):811-20
references.pmid: 22933029
references.citation: Int J Clin Pract. 2010 Sep;64(10):1425-35
references.pmid: 20579137
references.citation: Value Health. 2015 Jan;18(1):78-83
references.pmid: 25595237
references.citation: Clin Oncol (R Coll Radiol). 2006 Feb;18(1):67-9
references.pmid: 16477922
references.citation: Appl Health Econ Health Policy. 2013 Jun;11(3):163-80
references.pmid: 23529716
references.citation: Health Technol Assess. 2013 Jul;17(29):1-386
references.pmid: 23870108
references.citation: Health Educ Behav. 2013 Oct;40(5):603-11
references.pmid: 23345336
references.citation: Lung Cancer. 2010 Jan;67(1):4-11
references.pmid: 19939491
references.citation: Ann Oncol. 2005 Apr;16(4):579-84
references.pmid: 15734776
references.citation: Osteoarthritis Cartilage. 2013 Feb;21(2):289-97
references.pmid: 23182815
references.citation: Support Care Cancer. 2015 Jan;23 (1):21-8
references.pmid: 24939674
references.citation: Value Health. 2013 Jan-Feb;16(1):3-13
references.pmid: 23337210
references.citation: Clin Cancer Res. 2006 Oct 15;12(20 Pt 2):6243s-6249s
references.pmid: 17062708
references.citation: Support Care Cancer. 2013 Dec;21(12):3497-507
references.pmid: 23975226
references.citation: J Health Econ. 2009 Jul;28(4):894-901
references.pmid: 19464743
references.citation: J Clin Oncol. 2010 Dec 10;28(35):5132-9
references.pmid: 21060033
references.citation: Am J Manag Care. 2008 May;14(5):317-22
references.pmid: 18471035
references.citation: BMJ. 2004 Feb 14;328(7436):360-1
references.pmid: 14962852
references.citation: Lancet. 2011 Mar 5;377(9768):813-22
references.pmid: 21353695
references.citation: Health Econ. 2011 Mar;20(3):323-30
references.pmid: 20217834
references.citation: Curr Oncol. 2012 Dec;19(Suppl 3):S37-44
references.pmid: 23355792
references.citation: Pharmacoeconomics. 2011 Nov;29(11):977-88
references.pmid: 21854079
references.citation: Oncologist. 2005 Jan;10(1):52-62
references.pmid: 15632252
references.citation: Oncologist. 2004;9 Suppl 4:14-27
references.pmid: 15459426
references.citation: J Support Oncol. 2006 Jul-Aug;4(7):341-7
references.pmid: 16892696
references.citation: Cancer Res. 2004 Dec 15;64(24):9209-16
references.pmid: 15604294
references.citation: Palliat Med. 2015 Oct;29(9):842-50
references.pmid: 25805740